Quantcast
Last updated on April 24, 2014 at 5:01 EDT

Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

April 2, 2013

DUBLIN, April 2, 2013 /PRNewswire/ –

Research and Markets) has announced the addition of the “Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013” report to their offering

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.

The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.

Key content:

- A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis

- Biomarkers identified or further evaluated in the last three years, up until October 2011. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials

- Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers

- Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria

- Studies indicate drug type associations together with comparative therapies

- Descriptions and explanation of all biomarkers identified (proteins, genotypes, imaging etc)

- Biomarker associations are categorised according to three broad criteria, namely positive-therapy-indicating (response, improved response, improved outcome or prognosis), non-therapy-indicating (no differences in tumour response, outcome or prognosis) and negative-therapy-indicating (adverse events, poor outcome or prognosis)

Key Topics Covered:

Chapter 1: Background

Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Chapter 3 Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Chapter 4 Renal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Chapter 5 Ovarian Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
Chapter 6 Lung Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Chapter 7 Liver Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Chapter 8 Other Cancers: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Chapter 9: Discussion

For more information visit http://www.researchandmarkets.com/research/q3tlwb/vascular

Research and Markets is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends

Research and Markets Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


Source: PR Newswire